Psychology
Hepatitis C virus-infected patients with depression tolerate citalopram
Published in Hepatitis Weekly, March 1st, 2004
"Hepatitis C affects an estimated 4 million Americans and 100 million people worldwide. Rates of depression are higher than that seen in the general population. Antidepressant therapy is often initiated at lower doses in patients with liver disease because of concerns about impaired metabolism and clearance," scientists writing in the journal Psychosomatics report.
"This study assessed plasma levels of citalopram in 15 subjects with hepatitis C and major depression during an 8-week trial. The mean citalopram dose at study completion was 2667 mg/day."
...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
Source: Hepatitis Weekly (2004-03-01)
More Articles from Hepatitis Weekly
- Chemotherapy
Lamivudine maintains adriamycin intensity in hepatitis B patients with lymphoma - Adverse Drug Effects
APOE genotypes may influence a person's response to interferon-alpha - Fatty Liver
Genotype 3 increases the risk for steatosis in those infected with hepatitis C - Proteomics
A newly discovered mimotope could lead the way to HCV receptor antagonism - Public Health
Brazilian ex-soccer players may have spread hepatitis C with shared needles - Adverse Drug Effect
Atorvastatin causes asymptomatic elevations of liver enzyme levels - More from this issue of Hepatitis Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
